LEPR and glioblastoma: Targeting leptin signaling, by a selective leptin receptor antagonist peptide LDFI, completely reversed the leptin-mediated effects on cell growth and motility as well as reduced the expression of several leptin-induced target genes, confirming the relevant role of this adipokine in the biology of GBM.